Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital)

N/A

Report date: 2022/05/18 17:41:58

Base Information

Drug NameAnti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital)
Drug Alias Name抗CD19/CD20 CART转导的T细胞疗法TanCART-19/22 cells (Chinese PLA General Hospital)CD19/CD22 Tan CAR T Cells (Chinese PLA General Hospital)Genetically engineered lymphocyte therapy (Chinese PLA General Hospital)tanCART-19/22 cells (解放军总医院)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPeople'S Liberation Army General Hospital Military Service
China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital
Inactive CompaniesN/A
Active IndicationsLymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A